Biogen (BIIB) PT Raised to $320 at Oppenheimer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Biogen (BIIB) PT Raised to $320 at Oppenheimer

RBC Capital on Biogen (BIIB): 'FDA Summary Review Now Available; We Believe Suggests High Amenability For Future Full Leca Approval'

January 10, 2023 9:50 AM EST

RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $362.00 price target on Biogen (NASDAQ: BIIB).

The analyst comments "FDA's Summary Review of Leqembi (lecanemab) is now available, and we analyzed it in depth. Overall, given that the benefit/risk assessment appeared... More